Antiviral Drug News and Research

RSS

Study reveals the potential of novel antiviral drug combinations to stop COVID-19 spread

Researchers from Columbia Engineering, Fiocruz's Center for Technological Development in Health and the Oswaldo Cruz Institute in Brazil, Memorial Sloan Kettering Cancer Center, and Rockefeller University recently reported that, by combining inhibitors of polymerases and exonucleases--enzymes that allow SARS-CoV-2 to reproduce--they were able to reduce SARS-CoV-2 replication 10 times more than when using just the polymerase inhibitors.

7 Mar 2022

Identification of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding

Researchers discovered compounds able to inhibit SARS-CoV-2 macrodomain 1 and adenosine diphosphate-ribose binding via high throughput screening.

7 Mar 2022

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Researchers found that an antiviral drug, was effective against SARS-CoV-2 variants, including the recently emerged Omicron variant, in Syrian hamsters.

1 Mar 2022

Study reveals new way viruses trigger autoimmunity

Autoimmune diseases such as rheumatoid arthritis and Type 1 diabetes are thought to arise when people with a genetic susceptibility to autoimmunity encounter something in the environment that triggers their immune systems to attack their own bodies.

28 Feb 2022

Mouse-adapted virus model to study persistent COVID induced lung disease

Researchers develop a mouse model to identify early biomarkers and test countermeasures needed to detect and prevent PASC.

21 Feb 2022

Broad-spectrum antiviral activity of picolinic acid against SARS-CoV-2 and Influenza A virus

Researchers investigate the potential of picolinic acid (PA) as an anti-SARS-CoV-2 treatment option.

21 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Ensitrelvir, a novel SARS-CoV-2 antiviral

S-217622 reduces the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters.

17 Feb 2022

Researchers discover a novel group of proteins that exists in all domains of life

Proteins are the "workhorses" in every living cell and constitute the chemical basis of life. These little machines are required to turn food into energy, to manage motion and brain activities and to fight off bacteria and viruses.

17 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Treating COVID with antibiotics could be a much simpler way of making people better

A recent study conducted in an Egyptian hospital showed that treating moderate-to-severe COVID patients with either one of two antibiotics (ceftazidime or cefepime, in combination with a steroid) resulted in similar recovery times compared to patients given standard treatment.

29 Jan 2022

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Researchers investigate the possible efficacy of IFN-λ in the context of SARS-CoV-2 infection in mice.

28 Jan 2022

Paxlovid provides a glimpse into the future against SARS-CoV-2

A recent study reveals that nirmatrelvir is potent and effective against the SARS-CoV-2 Omicron variant.

23 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

A recent review discusses the engineering versatility of polymeric nanoparticles - making a good therapeutic alternative against coronavirus diseases.

19 Jan 2022

New findings support the routine use of remdesivir in hospitalized COVID-19 patients

Remdesivir, an antiviral drug used to treat COVID-19, increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study authored by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, HCA Healthcare, and Genospace.

18 Jan 2022

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

In a study posted to the bioRxiv* pre-print server, a team of researchers conducted a structure-activity relationship study of boceprevir-based molecules to find antiviral drug candidates targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease MPro.

22 Dec 2021

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

A University of Florida Health researcher has successfully analyzed the many mutations in the omicron variant of the SARS-CoV-2 virus, a crucial step in better understanding the variant's potential threat and ways to combat it.

9 Dec 2021

The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2

New research reports 4’-Fluorouridine (4′-FlU) as an oral antiviral against RSV and SARS-CoV-2.

7 Dec 2021